Literature DB >> 12547981

Executive dysfunction following traumatic brain injury: neural substrates and treatment strategies.

Brenna C McDonald1, Laura A Flashman, Andrew J Saykin.   

Abstract

Executive dysfunction is among the most common and disabling aspects of cognitive impairment following traumatic brain injury (TBI), and may include deficits in reasoning, planning, concept formation, mental flexibility, aspects of attention and awareness, and purposeful behavior. These impairments are generally attributed to frontal systems dysfunction, due either to direct insult to the frontal lobes or to disruption of their connections to other brain regions. Evaluation of executive deficits typically includes neuropsychological assessment, though adjunctive interviews can be critical in detecting subtle dysexecutive symptoms that may not be apparent on standardized testing. Rehabilitation programs emphasizing cognitive-behavioral approaches to the retraining of planning and problem-solving skills can be effective in ameliorating identified executive deficits. In addition, pharmacological approaches may be useful in addressing aspects of executive dysfunction. This review summarizes the nature of executive deficits following TBI, their neuroanatomical substrates, selected assessment and treatment strategies, and recent research findings and trends.

Entities:  

Mesh:

Year:  2002        PMID: 12547981

Source DB:  PubMed          Journal:  NeuroRehabilitation        ISSN: 1053-8135            Impact factor:   2.138


  57 in total

1.  Examination of the construct validity of ImPACT™ computerized test, traditional, and experimental neuropsychological measures.

Authors:  A Maerlender; L Flashman; A Kessler; S Kumbhani; R Greenwald; T Tosteson; T McAllister
Journal:  Clin Neuropsychol       Date:  2010-10-04       Impact factor: 3.535

2.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

3.  Increased brain activation during working memory processing after pediatric mild traumatic brain injury (mTBI).

Authors:  Daniel R Westfall; John D West; Jessica N Bailey; Todd W Arnold; Patrick A Kersey; Andrew J Saykin; Brenna C McDonald
Journal:  J Pediatr Rehabil Med       Date:  2015

Review 4.  Cognitive and Affective Symptoms Experienced by Cancer Patients Receiving High-Dose Intravenous Interleukin 2 Therapy: An Integrative Literature Review.

Authors:  Tara K Mann; Robin B Dail; Donald E Bailey
Journal:  Cancer Nurs       Date:  2016 Sep-Oct       Impact factor: 2.592

5.  Disturbed cortico-subcortical interactions during motor task switching in traumatic brain injury.

Authors:  Inge Leunissen; James P Coxon; Monique Geurts; Karen Caeyenberghs; Karla Michiels; Stefan Sunaert; Stephan P Swinnen
Journal:  Hum Brain Mapp       Date:  2012-01-30       Impact factor: 5.038

6.  ERPs predict symptomatic distress and recovery in sub-acute mild traumatic brain injury.

Authors:  James F Cavanagh; J Kevin Wilson; Rebecca E Rieger; Darbi Gill; James M Broadway; Jacqueline Hope Story Remer; Violet Fratzke; Andrew R Mayer; Davin K Quinn
Journal:  Neuropsychologia       Date:  2019-06-19       Impact factor: 3.139

Review 7.  Cognitive sequelae of traumatic brain injury.

Authors:  Amanda R Rabinowitz; Harvey S Levin
Journal:  Psychiatr Clin North Am       Date:  2014-01-14

8.  Neuropsychological Profile of Lifetime Traumatic Brain Injury in Older Veterans.

Authors:  Allison R Kaup; Carrie Peltz; Kimbra Kenney; Joel H Kramer; Ramon Diaz-Arrastia; Kristine Yaffe
Journal:  J Int Neuropsychol Soc       Date:  2016-10-04       Impact factor: 2.892

9.  Neurobehavioral sequelae of traumatic brain injury: evaluation and management.

Authors:  Thomas W McAllister
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

10.  Experimental traumatic brain injury alters ethanol consumption and sensitivity.

Authors:  Jennifer L Lowing; Laura L Susick; James P Caruso; Anthony M Provenzano; Ramesh Raghupathi; Alana C Conti
Journal:  J Neurotrauma       Date:  2014-09-02       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.